{
    "clinical_study": {
        "@rank": "21539", 
        "arm_group": [
            {
                "arm_group_label": "1 (Dietary Supplement - Fish Oil)", 
                "arm_group_type": "Experimental", 
                "description": "On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.\nOn Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
            }, 
            {
                "arm_group_label": "2 (Placebo)", 
                "arm_group_type": "Experimental", 
                "description": "On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.\nOn Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to determine the acute and chronic [4-week] effects of a\n      high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of\n      cardiovascular disease risk, in adults on Statin therapy."
        }, 
        "brief_title": "Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "detailed_description": {
            "textblock": "This study involves fasted and post-prandial components.\n\n      Fasted Study:\n\n      Participants will provide fasting blood samples pre-and post-intervention [4-week\n      administration of supplement or placebo] in Treatment Period I.  Participants will again\n      provide fasting blood samples pre-and post-intervention [4-week administration of supplement\n      or placebo, opposite to Treatment Period I] during Treatment Period II.\n\n      There will be a 4-week washout period during the two Treatment Periods.\n\n      Post-prandial study:\n\n      Participants will also complete a post-prandial study pre-and post-intervention during each\n      Treatment Period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be an adult between the ages of 18 and 70;\n\n          -  Be a male or a post-menopausal female who has gone a minimum of one year since their\n             last menses;\n\n          -  Be taking Statin medication at a stable dose for a minimum of  four weeks prior to\n             study commencement [and whom have reached a target LDL level];\n\n          -  Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7\n             mmol/L];\n\n          -  Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];\n\n          -  Have a Body Mass Index (BMI) less than 35.0\n\n          -  Be taking natural health products BUT agree to cease consumption during the study\n             period and a 4-week pre-study washout prior to study commencement.  Study\n             participants will be allowed to consume a daily multivitamin if they have been doing\n             so at a stable dose for a minimum of three months prior to study commencement.\n\n        Exclusion Criteria:\n\n          -  Be younger than 18 years of age or older than 70 years of age;\n\n          -  Be an adult pre- or peri-menopausal female;\n\n          -  Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to\n             study commencement;\n\n          -  Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or\n             greater than 5.7 mmol/L];\n\n          -  Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];\n\n          -  Have high blood pressure [greater than 140/100]\n\n          -  Have a Body Mass Index (BMI) equal to or greater than 35.0\n\n          -  Have a pre-existing cardiovascular disease or illness, including angina, myocardial\n             infarction, stroke, intermittent claudication or transient ischemic attack;\n\n          -  Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;\n\n          -  Be taking natural health products but are unwilling to cease consumption during the\n             study period and a 4-week pre-study washout prior to study commencement;\n\n          -  Consume more than two (2) fish meals on a weekly basis\n\n          -  Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks\n             per week];\n\n          -  Anticipate or have planned surgery during the course of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690312", 
            "org_study_id": "11-09-002", 
            "secondary_id": "150038"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 (Dietary Supplement - Fish Oil)", 
                "description": "On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].", 
                "intervention_name": "Fish Oil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "2 (Placebo)", 
                "description": "On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Humans", 
            "Cardiovascular Disease", 
            "Statins", 
            "Fish Oil", 
            "DHA", 
            "EPA", 
            "High-DHA", 
            "Triglycerides", 
            "Total cholesterol [TC]", 
            "Lipoproteins", 
            "High-density lipoprotein [HDL2, HDL3]", 
            "Low-density lipoprotein [LDL1+2+3+4]", 
            "Lipoprotein A [Lp(a)]", 
            "Intermediate-density lipoprotein (IDL)", 
            "Very low-density lipoprotein (VLDL1+2, VLDL3)", 
            "Remnant Lipoproteins", 
            "High-sensitivity C-Reactive Protein [hs-CRP]", 
            "Homocysteine", 
            "Essential Fatty Acid Profile", 
            "Apolipoprotein B", 
            "Apolipoprotein A-1", 
            "Glucose", 
            "Insulin", 
            "Fasted", 
            "Post-Prandial"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guelph", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N1G 0B4"
                }, 
                "name": "Nutrasource Diagnostics Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.", 
        "overall_official": {
            "affiliation": "University of Guelph", 
            "last_name": "Alison Duncan, Ph.D., R.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Fasted and postprandial samples will be drawn (hourly up to 6 hours).", 
            "measure": "Triglyceride [TG]", 
            "safety_issue": "No", 
            "time_frame": "0 and 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690312"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).", 
                "measure": "Glucose", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).", 
                "measure": "Insulin", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Total cholesterol [TC]", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "High-density lipoprotein [HDL]", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Low-density lipoprotein [LDL]", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Very low-density lipoprotein [VLDL]", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Lipoprotein A", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Intermediate-density lipoprotein [IDL]", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Remnant Lipoproteins", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "High-sensitivity C-Reactive Protein [hs-CRP]", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Homocysteine", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Essential Fatty Acid Profile", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Apolipoprotein B", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }, 
            {
                "description": "A fasted blood sample will be taken.", 
                "measure": "Apolipoprotein A-1", 
                "safety_issue": "No", 
                "time_frame": "0 and 4 weeks"
            }
        ], 
        "source": "Nutrasource Diagnostics Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Biodroga Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "University of Guelph", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Nutrasource Diagnostics Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}